|Ages Eligible for Study:||18 Years|
|Genders Eligible for Study:||Both|
|Accepts Healthy Volunteers:||No|
1. Patients must provide written informed consent prior to performance of study-specific
procedures or assessments, and must be willing to comply with treatment and follow
2. Patients with the following tumour types where VEGF inhibition would be appropriate
a Renal cell carcinoma (1L, 2L, excluding previous Tyrosine Kinase Inhibitors Rx) b
Ovarian carcinoma with a rising CA-125, 2nd or subsequent lines c Ovarian carcinoma
with residual disease after chemotherapy in the absence of rising CA-125, 2nd or
subsequent lines d Cervical cancer, metastatic or recurrent, and progressing after
conventional chemotherapy e Glioblastoma, progressing after conventional chemotherapy
f Advanced or metastatic soft tissue sarcoma, residual disease post chemotherapy in
the absence of progression, 2nd or subsequent lines g Non-small cell lung cancer, 1st
or subsequent lines h ErbB2 positive, advanced or metastatic breast cancer, 2nd or
subsequent lines i Gemcitabine-refractory pancreatic cancer, 2nd or subsequent lines
j Non-cutaneous (ocular or mucosal) melanoma and cutaneous melanoma any line k GI
tract 2nd line residual disease or subsequent lines l Small Cell Lung cancer 3rd line
m Other solid tumours in which anti-VEGF therapy is judged by the CI to be of
possible clinical benefit
3. Measurable disease as per RECIST 1.1.
4. ECOG performance status 0 or 1.
5. Age ?18 years.
6. Adequate organ system function
7. Female participant, or female partner of male participant, are of non-childbearing
potential or agree to protocol-specified contraceptive measures
1. Known hypertension (blood pressure >140/90 mmHg) at baseline
2. On anti-hypertensive therapy
3. History of any one or more of the following cardiovascular conditions:
a Cardiac angioplasty or stenting b Myocardial infarction c Unstable angina d
Coronary artery bypass graft surgery e Peripheral vascular disease or Raynaud's
phenomenon f Cerebrovascular accident (CVA) including transient ischaemic attack
(TIA), g Class III or IV congestive heart failure, as defined by the New York Heart
4. Hypersensitivity to agents used in forearm blood flow studies
5. Difficult upper limb arterial access
6. Diabetes, on oral therapy/insulin
7. Anticoagulant therapy (warfarin).
8. Pregnant or lactating female
9. Central nervous system (CNS) metastases.
10. Gastrointestinal abnormalities that may increase the risk for GI bleeding
11. Clinically significant gastrointestinal abnormalities that may affect absorption of
12. Presence of uncontrolled infection
13. Corrected QT interval (QTc) > 480 msecs using Bazett's formula
14. History of pulmonary embolism or untreated deep venous thrombosis (DVT) within the
past 6 months
15. Prior major surgery or trauma within 28 days prior to first dose and/or presence of
any non-healing wound, fracture, or ulcer.
16. Evidence of active bleeding or bleeding diathesis
17. Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels
18. Significant haemoptysis within prior 6 weeks
19. Pre-existing medical, psychiatric, or other condition that could interfere with
patient's safety, provision of informed consent, or compliance to study procedures.
20. Unable or unwilling to discontinue use of prohibited medications for at least 14 days
or five half-lives of a drug (whichever is longer) prior to the first dose of
pazopanib and for the duration of the study.
21. Treatment with any of the following anti-cancer therapies:
a radiation therapy, surgery or tumour embolization within 14 days prior to the first
dose of pazopanib OR b chemotherapy, immunotherapy, biologic therapy, investigational
therapy or hormonal therapy within 14 days or five half-lives of a drug (whichever is
longer) prior to the first dose of pazopanib c pazopanib or other antiangiogenic
treatment (e.g. bevacizumab)
22. Any ongoing toxicity from prior anti-cancer therapy that is >Grade 1 and/or that is
progressing in severity, except alopecia.
23. Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs
chemically related to pazopanib